Literature DB >> 31249459

Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction.

Chun-Chi Chiou1, Tzu-Hsien Tsai2, Chien-Ho Lee2, Cheng-Jei Lin2, Wen-Jung Chung2, Shu-Kai Hsuch2, Po-Jui Wu2, Cheng-I Cheng2.   

Abstract

BACKGROUND: Controlling modifiable risk factors (MRFs) in patients with cardiovascular diseases has been shown to be effective in reducing re-hospitalization rates. The aim of this study was to investigate the rates of controlled MRFs and clinical outcomes after pharmacist interventions in patients with myocardial infarction (MI) after hospital discharge.
METHODS: This prospective randomized clinical study was conducted at one medical center in Taiwan, and enrolled patients with MI from January 1, 2012 to December 31, 2014. Patients received medication reconciliation and education from a pharmacist before hospital discharge. The intervention group (IG) received continuous consultations from the pharmacist after discharge, whereas the control group (CG) did not. Primary outcomes included achieving blood pressure < 140/70 mmHg, low-density lipoprotein-cholesterol (LDL-C) < 70 mg/dL, and hemoglobin A1c (HbA1c) < 7% targets. The secondary outcome was major adverse cardiac events (MACEs), defined as re-hospitalization due to MI, unstable angina and stroke.
RESULTS: Two hundred and eight patients completed the study protocol (106 in the IG and 102 in the CG). The rate of achieving blood pressure goal was similar between the two groups. More patients in the IG achieved LDL-C and HbA1c goals than those in the CG at 1 year and 2 years post discharge. However, there was no significant difference in the cumulative incidence of MACEs between the two groups (5.7% vs. 9.8%) (p = 0.262). Diabetes was the only independent predictor of re-hospitalization due to a MACE.
CONCLUSIONS: Pharmacist interventions led to a higher rate of optimal controlled MRFs but did not significantly reduce the MACE rate in the patients with MI.

Entities:  

Keywords:  Clinical outcome; Myocardial infarction; Pharmacist intervention

Year:  2019        PMID: 31249459      PMCID: PMC6533579          DOI: 10.6515/ACS.201905_35(3).20181122B

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  37 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

3.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 4.  Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Authors:  John B Buse; Henry N Ginsberg; George L Bakris; Nathaniel G Clark; Fernando Costa; Robert Eckel; Vivian Fonseca; Hertzel C Gerstein; Scott Grundy; Richard W Nesto; Michael P Pignone; Jorge Plutzky; Daniel Porte; Rita Redberg; Kimberly F Stitzel; Neil J Stone
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

5.  Contemporary management of dyslipidemia in high-risk patients: targets still not met.

Authors:  Andrew T Yan; Raymond T Yan; Mary Tan; Daniel G Hackam; Kori L Leblanc; Heather Kertland; Jennifer L Tsang; Shahin Jaffer; Martin L Kates; Lawrence A Leiter; David H Fitchett; Anatoly Langer; Shaun G Goodman
Journal:  Am J Med       Date:  2006-08       Impact factor: 4.965

6.  Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).

Authors:  K A A Fox; S G Goodman; W Klein; D Brieger; P G Steg; O Dabbous; A Avezum
Journal:  Eur Heart J       Date:  2002-08       Impact factor: 29.983

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure.

Authors:  James C Coons; Toni Fera
Journal:  Am J Health Syst Pharm       Date:  2007-06       Impact factor: 2.637

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  3 in total

1.  Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

2.  Clinical Nomogram to Predict Major Adverse Cardiac Events in Acute Myocardial Infarction Patients within 1 Year of Percutaneous Coronary Intervention.

Authors:  Defeng Pan; Shengjue Xiao; Yue Hu; Qinyuan Pan; Qi Wu; Xiaotong Wang; Qiaozhi Liu; Ailin Liu; Jie Liu; Hong Zhu; Yufei Zhou
Journal:  Cardiovasc Ther       Date:  2021-12-13       Impact factor: 3.023

3.  Variation in Blood Pressure Classification Using 7 Blood Pressure Estimation Protocols Among Adults in Taiwan.

Authors:  Hung-Ju Lin; Heng-Yu Pan; Wen-Jone Chen; Tzung-Dau Wang
Journal:  JAMA Netw Open       Date:  2020-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.